Abstract
Many natural and synthetic compounds bind to tubulin, an ubiquitous globular protein that provides the building blocks for the cellular microtubule network that controls chromosome segregation during mitosis, vesicle movements, intracellular transport of organelles, ciliar and flagellar movement, and maintenance of cell shape. Since the isolation of the antimitotic marine natural product curacin A in 1994, synthetic work on this colchicine-site binding agent has been intense, but only recently have synthetic derivatives been identified that match its potency for tubulin polymerization inhibition and its high level of growth inhibition in cancer cell lines. In addition to several total synthesis efforts, combinatorial libraries were constructed using solution phase and fluorous scavenging approaches. Low watersolubility and lack of chemical stability represent strong detriments for the clinical development of curacin A, but synthetic analogs with improved bioavailability might ultimately probe the paradigm for anticancer efficacy of colchicinesite tubulin binding agents.
Keywords: curacin a, colchicine, tubulin, antimitotic agents, bioisosteres, anticancer activity, sar, natural products
Current Pharmaceutical Design
Title: Chemistry and Biology of Curacin A
Volume: 10 Issue: 12
Author(s): Peter Wipf, Jonathan T. Reeves and Billy W. Day
Affiliation:
Keywords: curacin a, colchicine, tubulin, antimitotic agents, bioisosteres, anticancer activity, sar, natural products
Abstract: Many natural and synthetic compounds bind to tubulin, an ubiquitous globular protein that provides the building blocks for the cellular microtubule network that controls chromosome segregation during mitosis, vesicle movements, intracellular transport of organelles, ciliar and flagellar movement, and maintenance of cell shape. Since the isolation of the antimitotic marine natural product curacin A in 1994, synthetic work on this colchicine-site binding agent has been intense, but only recently have synthetic derivatives been identified that match its potency for tubulin polymerization inhibition and its high level of growth inhibition in cancer cell lines. In addition to several total synthesis efforts, combinatorial libraries were constructed using solution phase and fluorous scavenging approaches. Low watersolubility and lack of chemical stability represent strong detriments for the clinical development of curacin A, but synthetic analogs with improved bioavailability might ultimately probe the paradigm for anticancer efficacy of colchicinesite tubulin binding agents.
Export Options
About this article
Cite this article as:
Wipf Peter, Reeves T. Jonathan and Day W. Billy, Chemistry and Biology of Curacin A, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384853
DOI https://dx.doi.org/10.2174/1381612043384853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogen Receptor: Structural Differences and Potential Implications on Selectivity Examined by the GRID/CPCA Approach
Letters in Drug Design & Discovery Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Synthesis and Preliminary Biological Evaluation of New Heterocyclic Carboxamide Models
Letters in Drug Design & Discovery Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics A Molecular Guidance System Based Upon Target Genes, Nuclear Receptors and Ligands Applied to Drug Discovery and Prediction of Toxicity
Mini-Reviews in Medicinal Chemistry DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Meet Our Editor
Current Analytical Chemistry Editorial [Hot Topic:Recent Advances in Developmental and Reproductive Toxicology (Executive Editor: Gian Mario Tiboni )]
Current Pharmaceutical Design A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Damnacanthal: A Promising Compound as a Medicinal Anthraquinone
Anti-Cancer Agents in Medicinal Chemistry Features Identification for Phenotypic Classification Based on Genes and Gene Pairs
Current Bioinformatics Synthesis and Preliminary Screening of Novel A- and D-Ring Modified Steroids as Aromatase Inhibitors
Letters in Drug Design & Discovery Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry